TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Sunday.
Other analysts have also issued reports about the company. Lake Street Capital decreased their price target on TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, May 13th. Weiss Ratings restated a “sell (e+)” rating on shares of TriSalus Life Sciences in a report on Friday, August 7th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $7.50.
Get Our Latest Analysis on TriSalus Life Sciences
TriSalus Life Sciences Stock Down 3.0%
TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.16) earnings per share for the quarter, meeting the consensus estimate of ($0.16). The business had revenue of $11.41 million during the quarter, compared to analyst estimates of $10.27 million.
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the company. Bank of America Corp DE lifted its position in shares of TriSalus Life Sciences by 1.8% in the 2nd quarter. Bank of America Corp DE now owns 188,906 shares of the company’s stock worth $1,030,000 after buying an additional 3,374 shares during the last quarter. Millennium Management LLC lifted its position in TriSalus Life Sciences by 17.7% in the 3rd quarter. Millennium Management LLC now owns 35,612 shares of the company’s stock valued at $166,000 after purchasing an additional 5,359 shares during the last quarter. JPMorgan Chase & Co. lifted its position in TriSalus Life Sciences by 35,804.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock valued at $41,000 after purchasing an additional 7,519 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in TriSalus Life Sciences during the 2nd quarter valued at about $47,000. Finally, Cura Wealth Advisors LLC acquired a new position in TriSalus Life Sciences during the 2nd quarter valued at about $36,000. Institutional investors own 2.58% of the company’s stock.
TriSalus Life Sciences Company Profile
TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.
The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.
See Also
- Five stocks we like better than TriSalus Life Sciences
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
